venous thromboembolism
Study compares dabigatran to warfarin in VTE treatment
- Tue, 05/29/2012 - 11:06am
A study conducted primarily by Boehringer Ingelheim, the maker of Pradaxa, suggests a fixed dose of dabigatran therapy
-
Ariad asks FDA for priority review of leukemia drug
- Jul 31, 2012
-
Fosamax linked to femoral fractures and other injuries
- Jun 30, 2011
-
FDA OKs new meningitis vaccine for babies
- Jun 15, 2012
-
Take Fosamax and other bisphosphonates for 5+ years and break your thigh bone
- May 24, 2012
-
CooperVision® issues Avaira® contact lens recall
- Nov 16, 2011
-
Pradaxa® prescribing errors: Cause of side effects?
- Mar 6, 2012
-
FDA issues warning after codeine kills children post-surgery
- Aug 16, 2012
-
Artificial retina gives sight to blind mice
- Aug 16, 2012
-
Lucentis approved for diabetic macular edema
- Aug 14, 2012
-
Mayo Clinic: Patients in the dark about prescriptions
- Aug 9, 2012
-
Hospital's plan to prevent painkiller abuse
- Aug 8, 2012
-
Alzheimer's drug disappoints
- Aug 8, 2012
lawsuits blood clots Nature diet drug fentanyl patch Zimmer type 2 diabetes Pradaxa diet pill Inspiration prescription drugs statin settlement pulmonary embolism Lexapro liver damage Technology Tempah Yaz bladder cancer Xarelto HIV test Roche Accutane heart attack dabigatran Products lawsuit Fosamax venous thromboembolism
More Dangerous Drug News
Get News Updates By Email
@ConsumerDrugRep Tweets
Archives
- June 2011 (3)
- September 2011 (1)
- October 2011 (3)
- November 2011 (5)
- December 2011 (25)
- January 2012 (8)
- February 2012 (24)
- March 2012 (20)
- April 2012 (6)
- May 2012 (12)